Célèste Lebbé

Research interests

Publications

• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407417

• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  Zurich Open Repository and Archive (University of Zurich) · 2022 · https://doi.org/10.5167/uzh-213514

• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1904059

• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910836

• Merkel cell carcinoma

  Nature Reviews Disease Primers · 2017 · 10.1038/nrdp.2017.77

• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709684

• Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.67.9258

• Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30429-1

• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709030

• Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx176

• Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

  European Journal of Cancer · 2017 · 10.1016/j.ejca.2016.12.001

• Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.73.7379

• Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30364-3

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1611299

• Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

  European Journal of Cancer · 2015 · 10.1016/j.ejca.2015.06.110

• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)60898-4

• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70122-1

• Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70012-9

• Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1406037

• Nivolumab in Previously Untreated Melanoma without BRAF Mutation

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1412082

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782

• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1104621

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-09-1624

• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

  The Lancet Oncology · 2009 · 10.1016/s1470-2045(09)70334-1

Current projects

No projects listed.